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Abstract
Background: Elective knee surgery is performed to reduce chronic pain and improve function in degenerate knees.
Treatment of acute post-operative pain is suboptimal in 75% of patients despite multimodal analgesic approaches
resulting in higher post-operative opiate consumption. The effect of corticosteroids as an adjunct for post-operative
pain control remains undefined.
Methods: The databases MEDLINE, EMBASE and CENTRAL (Cochrane library) will be searched from their inception
to present using broad search criteria for eligible randomised/quasi-randomised controlled trials investigating
perioperative corticosteroid adjunctive use in elective knee surgery. Meta-analyses will be conducted according to
the recommendations from the Cochrane Handbook for Systematic Reviews of Interventions.
Discussion: This systematic review of the perioperative adjunctive use of corticosteroids will assess the analgesic
effects, post-operative nausea and vomiting, opiate consumption, infection rates and time till discharge and assess
whether adjunctive corticosteroids should be encouraged in elective knee surgery.
Systematic review registration: PROPSERO CRD42016049336
Keywords: Analgesia, Corticosteroids, Knee, Perioperative, Surgery
Background
Description of the condition
Treatment of acute post-operative pain following elect-
ive surgery is suboptimal with reports of up to 75% of
patients having inadequate pain relief in the immediate
post-operative period [1, 2].
Elective knee surgery is commonly performed to
reduce chronic pain and improve function in degenerate
knees. Approximately 160,000 knee and hip replace-
ments are conducted annually with demand on the rise
[3]. This is evidenced by the greater numbers of patients
having to wait beyond the 18-week target for elective
surgery. In 2014, 51,388 patients waited excess of this
period compared to 92,739 in 2015 [4].
Effective analgesia is therefore paramount to early
rehabilitation, deconditioning prevention and timely
discharge to free up resources. By the year 2030, the
demand for total knee arthroplasty alone is predicted to
grow sixfold placing emphasis on post-operative pain
optimization as a priority [5].
Traditionally, pain control following surgery heavily
relied on oral opiates and patient-controlled analgesia.
However unfortunately, opiates are associated with vari-
ous side effects, some of which include respiratory
depression, confusion, sedation, vomiting, pruritus and
urinary retention with evidence suggesting longer hos-
pital stays and higher socioeconomic costs. Furthermore,
the light sedation, muscle weakness and dizziness
opiates cause may have an impact on post-operative
rehabilitation delaying it or even predisposing to
increased risk of injuries [6, 7].
There is also evidence that optimization of immediate
post-operative analgesia reduces chronic post-surgical
pain occurrences and improves functional outcomes
significantly [8].
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Description of the intervention
The limitations of opiate therapy combined with a deep-
ening understanding of pain physiology and pathophysi-
ology has been paramount to developing alternative pain
management strategies.
Kehlet and Dahl [9] conceptualised the multimodal
analgesia model, in which a combination of different
analgesic classes used simultaneously act on different
pathways but in effect complement each other thereby
potentiating their analgesic effect. This in turn reduces
the reliance on opiates. Common medications used in a
multimodal approach include paracetamol, non-steroidal
anti-inflammatory drugs and gabapentinoids [9].
The effectiveness of adjunctive agents to the multi-
modal approach have been studied extensively for medi-
cations including ketamine, gabapentin and paracetamol
demonstrating clear benefits in reducing post-operative
pain and opiate consumption. As a result, these medica-
tions have become incorporated into most multimodal
approaches [10–12].
Corticosteroids are commonly used for post-operative
nausea and vomiting and may have a role in post-
operative pain control to further optimise current
approaches [13]. Often, randomised controlled studies
report conflicting results regarding their usage, and
therefore, corticosteroids effect on post-operative pain
remains undefined [14].
Corticosteroids have recently been used to reduce in-
flammation and damage to tissues in several conditions
including rheumatoid arthritis with early studies in the
dental field suggesting a role in reducing post-operative
pain and oedema [15].
Unfortunately, corticosteroids are not without their
side effects with reports of increased risk of infections,
osteoporosis, wound dehiscence and muscle weakness
[16]. Although these side effects usually refer to long-
term steroid usage (>3 weeks) and not in a perioperative
setting, their side effects must be monitored and the
lowest effective dosage utilised.
How the intervention might work
Corticosteroids can be divided into two main groups;
glucocorticoids and mineralocorticoids. Mineralocorti-
coids are involved in electrolyte and water balance and
are not utilised in multimodal pain management postop-
eratively. Therefore, when referring to corticosteroids in
our review, our emphasis is placed on the glucocorticoid
type.
During surgery, tissue injury initiates the release of
proinflammatory cytokines and prostaglandins that cas-
cade a pathway hypersensitising nociceptors thereby
generating pain.
It is believed that all glucocorticoids bind to specific
cytoplasmic glucocorticoid receptors thereby inhibiting
prostaglandins normally released in tissue injury and
hence the hypersensitisation process [17, 18]. Although
glucocorticoids are well known medications, their
precise mechanism of action remains unclear.
Furthermore, steroid hormone receptors are found
throughout the central and peripheral nervous systems
allowing them to assist regulate the growth, maturation
and differentiation of neurones. This suggests their role
is pivotal in pain perception [19]. Specifically, corticoste-
roids have been proved to reduce the spontaneous dis-
charge from damaged nerves thereby reducing pain [17].
Why is it important to do this review
Steroids have been utilised extensively for inflammatory
conditions, immunomodulation for organ transplant and
antiemetic properties in the immediate post-operative
period. In surgery, they are often utilised as an adjunct
in multimodal analgesic regimens although their effect
on post-operative pain remains undefined. It is also im-
portant to ensure that corticosteroid administration is
safe by monitoring their side effects such as infection
and poor wound healing [15].
A review in this field would allow us to conclude
whether or not adjunctive corticosteroid use has any ef-
fect on immediate post-operative pain. The results of
our review will inform us of whether steroids should be
incorporated into multimodal analgesic regimens for
elective knee surgery and would have implications for
elective surgery in general.
Objectives
The objective of this review was to assess the effect of
perioperative corticosteroids used as an adjuvant com-
pared to those without corticosteroids in patients aged
18 and over undergoing elective knee surgery, while tak-
ing into consideration the route of administration.
Methods/design
Study registration
The protocol is registered on PROPSERO with CRD
42016049336 and follows the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses Protocol
2015 (Additional file 1).
Criteria for considering studies for this review
Types of studies
We will include all randomised and quasi-randomised
controlled trials, including cluster trials if they have a
minimum of two comparison groups, one of which
includes adjunct corticosteroid usage. Studies will be
included irrespective of publication status or language.
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Types of participants
We will include all trials with patients over the age of 18
and older undergoing elective knee surgery with no
restriction on co-morbidities or ethnicity. Our definition
of elective knee surgery encompasses all types of knee
surgery, which includes total/partial knee arthroplasty,
knee arthroscopy, ligament reconstruction, meniscal
resection/repair and cartilage repair.
Types of interventions
Our definition of elective knee surgery is to encompass
all types of knee surgery which will include total/partial
knee arthroplasty, knee arthroscopy, ligament recon-
struction, meniscal resection/repair and cartilage repair.
We anticipate from our preliminary searches the vast
majority of studies investigating steroids in knee surgery
will fall broadly under arthroplasty or arthroscopy (given
most ligament repairs, meniscal resections and cartilage
are performed arthroscopically).
We will include all knee surgery procedures rando-
mised controlled trials comparing the effect of cortico-
steroid administration perioperatively as an additional
medication to standard analgesic therapy. Acceptable
routes of corticosteroid administration will include oral,
intravenous or intraarticular administration. Studies
reporting on preoperative, intraoperative and post-
operative administration will be included provided the
corticosteroid is administered within 24 h prior to the
procedure and no later than 24 h after surgery.
We will exclude papers administering steroids through
neurones/epidurals as these are user dependant and can
potentially damage nerves thereby confounding any
effect of steroid administration on pain.
Types of outcome measures
i) Primary outcomes
Mean pain score assessed on a pain scale at rest at
24 h following surgery. All pain scales reported by
the various studies will be considered.
ii) Secondary outcomes
a) Mean pain score
Mean pain score at rest assessed on a pain scale
at rest at 12, 48 and 72 h postoperatively. All pain
scales will be considered.
b) Opiate consumption
Mean opiate consumption in oral morphine
equivalents taken postoperatively over the first
24 h.
c) Nausea and vomiting
The risk of post-operative nausea and vomiting
(PONV) in the first 24 h postoperatively. We will
measure this as binary data. We will also describe
narratively the number of other gastrointestinal
complications including ulcers and GI bleeding.
d) Infection
The risk of infection during patient’s hospital stay
postoperatively. We will measure this as binary
data. We will narratively discuss the numbers of
superficial and deep infections if reported by
studies.
e) Time till discharge
The time till discharge postoperatively.
f ) Other adverse effects
Other adverse effects not falling into outcomes
stated. This would include delayed wound
healing, glucose levels if measured, diabetes
incidence and anything else reported in the
literature.
Electronic database searches
The following databases will be searched from their con-
ception to 10 October 2016
1) PUBMED/OVID MEDLINE
2) EMBASE
3) CENTRAL (Cochrane library)
Appropriate medical subject headings or their equiva-
lents were utilised for all databases searched using broad
search criteria to increase sensitivity of the search. The
broad fields included in the search will include surgery,
corticosteroids and pain along with all variants of the
terms. Additionally, the randomised controlled trial (RCT)
term was utilised in our search. The search strategy was
approved by an Oxford University Bodleian Librarian. The
search strategies for each database are highlighted in
Appendix 1.
Searching for other resources
Extracted paper bibliographies will be searched for any
articles that meet our inclusion criteria as well as by
observing other review articles in the field.
Data collection and analysis
Selection of studies
Studies collected from the search conducted will be
screened independently for inclusion by two authors
(HRM and TH) initially by title and abstract. Shortlisted
papers will have complete manuscripts obtained and
assessed using the eligibility criteria by (HRM and LS).
Any disagreements will be initially discussed between
HRM and LS and if no consensus reached by the in-
volvement of a third author (MT). If needs be, the senior
authors (DM, HP) will also be consulted.
The summary of the number of papers form search
results and at each step will be summarised in a
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PRISMA flowchart. The shortlisted papers will then be
screened for any duplicate data and be processed appro-
priately as per next section.
Data extraction and management
Data from the database search will be managed using
EndNote software. Results from the original search on
all databases will be merged and duplicates removed. All
papers will have their abstracts and titles read by two au-
thors (HM and TM) for shortlisting. Full papers will be
read if further details are required or there is disagree-
ment between the authors. If there is still disagreement,
a third author (HP) will be consulted.
Data extraction from shortlisted papers will be con-
ducted independently by two authors (HM and TH) and
recorded onto a standardised Microsoft excel database
with outcomes of interest. A third author (HP) will be
contacted if any inconsistency in data collection is ob-
served between the two authors. If additional informa-
tion is required for any of the included studies, the
corresponding authors for the papers will be contacted
by email.
From each paper, the following information will be ex-
tracted: author, country, year of study, procedure type,
type of anaesthesia, number of patients in each study
arm, treatment in each study arm, route and dosage of
steroid administration, all primary and secondary
outcomes as previously described with their standard
deviation (SD), confidence interval (CI) or standard
error (SE).
Assessment of risk of bias in included studies
Two review authors (HM and TH) will independently
assess the risk of bias (ROB) using the Cochrane Risk of
bias tool [20]. The studies will be assessed as ‘high’, ‘low’,
or ‘unclear’ risk of bias, and any judgement will be sup-
ported and reported, based on the information provided
in the studies. Consensus on the judgements will be
reached through discussion, and where necessary, a third
review author will be consulted.
The following domains will be assessed for each
included study
a) Random sequence generation
b) Allocation concealment
c) Blinding
d) Incomplete outcome data
e) Selective outcome reporting
f ) Other bias
Measures of treatment effect
The dosage of steroids administered will be converted
into oral prednisolone equivalents.
Outcomes of pain scores will be treated as continuous
variables. If studies report different pain scales, we will
explore whether widely accepted transformation tech-
niques are available for obtaining the equivalent (0-10)
VAS scores. If this is not possible, we will include these
data and opt for the standardised mean difference when
carrying out meta-analysis.
For continuous outcomes (time till discharge, opiate
consumption in morphine equivalents, and pain scores)
using the same measurement scales, we will record the
mean, standard deviation, and total number of partici-
pants in the treatment and control groups, and will ex-
press the treatment effect as the mean and 95% CI. If
outcomes are reported in different scales, we will use the
standardised mean difference (SMD).
For binary outcomes (post-operative nausea and
vomiting and infection), the risk ratio (RR) and 95% CI
will be calculated. If small numbers of events are re-
ported (<5% of the sample in each group), and the treat-
ment groups are balanced, we will report the Peto’s odds
ratio (Peto-OR) and 95% CI.
Unit of analysis issues
For outcomes pain at 12/24/48/72 h and infection, our
unit of analysis will be number of knees. For outcomes
nausea and vomiting, time till discharge, opiate con-
sumption and other adverse effects, unit of analysis will
be number of patients.
For studies involving multiple arms, where it is not
possible to combine arms, they will be analysed by divid-
ing either (i) the number of events and group size (for
dichotomous) or (ii) the group size (for continuous), in
the number of arms in the trial as appropriate.
If the search identifies eligible cluster trials, we will ob-
tain the interclass correlation (ICC) and will include the
cluster trials in the meta-analysis using the generic in-
verse variance method. If ICC is not available, we will
borrow an appropriate ICC from similar trials.
We are not expecting any cross-over trials as this
would be an inappropriate design in this case.
Dealing with missing data
Study authors will be contacted where possible to
recover as much missing information as possible. Rea-
sons for missing data will be explored through sensitivity
analysis.
Where data is demonstrated graphically with no nu-
merical description in the text, and if contact with study
authors is not possible, Measure C software will be uti-
lised to extrapolate the values from enlarged images of
the graphs to the nearest pixel [21]
We will not utilise multiple imputation given its contro-
versies for multiple scoring systems and potential small
sample sizes in some of the studies included [2, 22].
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Where data are not suitable for incorporation into
meta-analysis, information will be summarised as a nar-
rative or in tables, as appropriate.
Assessment of heterogeneity
We expect heterogeneity from measurement scales used
for our outcomes of interest and different types of knee
surgery procedures, and hence, we will be using the
random effects model in all meta-analyses.
We will explore heterogeneity using the I2 statistic and
classify it as substantial if I2 > 90%. Pooled results with
heterogeneity above this level will be interpreted with
caution, and we will check the magnitude and direction
of effects and the strength of evidence for heterogeneity
from the p value of the chi2 test. If appropriate, the
pooled result will not be reported.
We will also consider separately different group
categories of surgery types (i.e. knee replacement, knee
arthroplasty), as part of heterogeneity exploration.
Assessment of reporting bias
If there are more than 10 studies in our meta-analysis, we
will explore potential publication bias by a funnel plot.
Data synthesis
Where studies are sufficiently homogeneous, we will
carry out meta-analysis as per the Cochrane handbook
of Systematic Reviews of Interventions using Review
Manager 5.3 (RevMan 2014) [20].
We expect that pain will be reported in a number of
different pain scales, and hence, the pooled SMD and
95% CI will be estimated using the inverse variance
method. We will report the pooled results by back-
transforming it into the (0-10) visual analogue scale by
multiplying the SMD and 95% CI by the standard devi-
ation of the largest study control group reporting the
outcome of interest.
For dichotomous data, the pooled RR will be calcu-
lated using the Mantel-Hanzel method along with the
95% CI.
Where meta-analysis is not possible, we will report
findings as a narrative or table as appropriate.
As all corticosteroids (specifically glucocorticoids) are
thought to act in the same way, they will be no distinc-
tion (or subgroups) in the analysis. Different dosages will
be converted into oral prednisolone equivalents using
standard steroid conversion charts [23]. Similarly for
opiate consumption postoperatively, given they act on
the same pathway, they will be standardised into oral
morphine equivalents for comparative reasons using a
standardised opiate conversion chart [24].
Subgroup analysis and investigation of heterogeneity
If data allows it, we will explore the following subgroups:
a) Systemic corticosteroid (oral/iv) versus local
corticosteroid (intra/periarticular) on acute post-
operative pain.
b) The effect of corticosteroid on post-operative pain
in different types of knee surgery, i.e. arthroscopic
versus joint replacement.
c) Different adjuvant corticosteroid dosage on post-
operative pain. This will be based on the converted
prednisolone equivalent.
Sensitivity analysis
We will conduct sensitivity analysis based on blinding
and allocation concealment domains of the risk of bias
tool; high risk studies will be excluded from the analysis
to see how robust the result is.
Specifically for quasi-randomised studies, if they are
assessed as high risk of bias for the sequence generation
and allocation concealment domains of the risk of bias
tool, we will use sensitivity analysis to explore the effects
on the pooled results.
Summary of findings
We will use the GRADE tool to assess the quality of evi-
dence of the outcomes and will include the findings in a
‘Summary of findings’ (SOF) table according to the
Cochrane recommendations [25, 26]. The following out-
comes will be included in the SOF: mean pain scores at
12, 24, 48 and 72 h, opiate consumption over the first
24 h, nausea and vomiting over the first 24 h and infec-
tion rate.
Discussion
This review will assess the benefits and harms of peri-
operative adjunctive use of corticosteroids in knee
surgery. The multimodal analgesic approach has reduced
the post-operative use of oral opiates, but there is room
for improvement given 75% of patients still report inad-
equate pain relief in the immediate post-operative
period.
Our preliminary searches have not demonstrated any
obvious issues conducting the GRADE assessment in
our review and that most studies are adequate sized with
a sample size above 50 patients in total, with a range of
n = 30 to n = 270.
However, we have identified that a few papers have
not reported the CI/SE/SD for the pain scores reported.
We will attempt to contact authors for this informa-
tion. Failing this if the results are illustrated graphically,
we will use Measure C software to extrapolate these
readings. If this is not available, then whatever data is
available will be reported narratively and not included
in the meta-analysis.
Furthermore, although most studies report pain on
the visual analogue scale, there are two papers that
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report pain on other scales. One reports the pain
outcome on the verbal response scale and the other on
the visual descriptor scale. Given that these cannot be
converted into the visual analogue scale, these will be
reported narratively but not included in the meta-
analysis.
A couple of papers have reported the outcome pain as
a median with an interquartile range. Again, this will be
described narratively and not included in the meta-
analysis.
One paper from our search was only available in
Persian and will therefore need to be translated to
extract the data of interest. All other papers are readily
available in English.
Our preliminary search demonstrated year of publica-
tions from 1993 to 2016. Papers from the 1990s may
prove difficult to contact the authors for further infor-
mation given they were published a long time ago.
In conclusion, we do not anticipate any major
concerns conducting this review and issues described
above should be relatively straightforward to manage.
Appendix 1
Ovid Medline search strategy
1 Steroids/or HYDROCORTISONE/or BETAMETHA
SONE/or Prednisolone/or Dexamethasone/or Triam-
cinolone/or Cortisone/or Glucocorticoids/or Adrenal-
Cortex-Hormones/or Corticosterone/or Hydrocortisone/
or 18-Hydroxycorticosterone/or Tetrahydrocortisol/
or Tetrahydrocortisone/or Desoxycorticosterone/or 18-
Hydroxydesoxycorticosterone/
2 ("adrenal cortex hormon$" or steroid$ or cortico-
sterone or corticosteroid$ or cortisol$ or hydrocortisone$
or 18-hydroxycorticosterone or cortison$ or tetrahydro
cortisol or hydrocortison$ or betamethason$ or predniso-
lon$ or methylprednisolon$ or dexamethason$ or triamci-
nolon$ or deflazacort$).ti,ab.
3 1 or 2
4 Surgical Procedures, Operative/or Surgery/or
Perioperative-Care/
5 (surg$ or operat$ or (perioperative adj3 care)).mp.
[mp = title, abstract, original title, name of substance
word, subject heading word, keyword heading word,
protocol supplementary concept word, rare disease sup-
plementary concept word, unique identifier]
6 4 or 5
7 Pain, Postoperative/
8 ((postoperative adj4 pain*) or (post-operative adj4
pain*) or post-operative-pain* or (post* adj4 pain*) or
(postoperative adj4 analgesi*) or (post-operative adj4
analgesi*) or "post-operative analgesi*").mp.
9 ((post-surgical adj4 pain*) or ("post surgical" adj4
pain*) or (post-surgery adj4 pain*)).mp.
10 ("pain-relief after surg*" or "pain following surg*" or
"pain control after").mp.
11 (("post surg*" or post-surg*) and (pain* or
discomfort)).mp.
12 ((pain* adj4 "after surg*") or (pain* adj4 "after
operat*") or (pain* adj4 "follow* operat*") or (pain* adj4
"follow* surg*")).mp.
13 ((analgesi* adj4 "after surg*") or (analgesi* adj4
"after operat*") or (analgesi* adj4 "follow* operat*") or
(analgesi* adj4 "follow* surg*")).mp.
14 7 or 8 or 9 or 10 or 11 or 12 or 13
15 (randomised controlled trial or controlled clinical
trial).pt. or randomised.ab. or placebo.ab. or clinical
trials as topic.sh. or randomly.ab. or trial.ti.
16 3 and 6 and 14 and 15
EMBASE search strategy
1 steroid/or hydrocortisone/or betamethasone/or
prednisolone/or dexamethasone/or triamcinolone/or
cortisone/or glucocorticoid/or corticosterone/or hydro-
cortisone/or 18-hydroxycorticosterone/or tetrahydrocor-
tisol/or tetrahydrocortisone/or deoxycorticosterone/or
18-hydroxydeoxycorticosterone/
2 (adrenal cortex hormon$ or steroid$ or cortico-
sterone or corticosteroid$ or cortisol$ or hydrocorti-
sone$ or 18-hydroxycorticosterone or cortison$ or
tetrahydrocortisol or hydrocortison$ or betamethason$
or prednisolon$ or methylprednisolon$ or dexametha-
son$ or triamcinolon$ or deflazacort$).ti,ab.
3 1 or 2
4 surgical-technique/or surgery/or perioperative-
period/or (surg$ or operat$ or (perioperative adj3
care)).ti,ab.
5 Pain, Postoperative/
6 ((postoperative adj4 pain*) or (post-operative adj4
pain*) or post-operative-pain* or (post* adj4 pain*) or
(postoperative adj4 analgesi*) or (post-operative adj4
analgesi*) or "post-operative analgesi*").mp.
7 ((post-surgical adj4 pain*) or ("post surgical" adj4
pain*) or (post-surgery adj4 pain*)).mp.
8 ("pain-relief after surg*" or "pain following surg*" or
"pain control after").mp.
9 (("post surg*" or post-surg*) and (pain* or
discomfort)).mp.
10 ((pain* adj4 "after surg*") or (pain* adj4 "after
operat*") or (pain* adj4 "follow* operat*") or (pain* adj4
"follow* surg*")).mp.
11 ((analgesi* adj4 "after surg*") or (analgesi* adj4
"after operat*") or (analgesi* adj4 "follow* operat*") or
(analgesi* adj4 "follow* surg*")).mp.
12 5 or 6 or 7 or 8 or 9 or 10 or 11
13 3 and 4 and 12
14 (placebo.sh. or controlled study.ab. or random*.-
ti,ab. or trial*.ti,ab.) and human*.ec,hw,fs.
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15 13 and 14
16 1 or 2
17 4 and 12 and 14 and 16
CENTRAL search strategy
ID Search Hits
#1 MeSH descriptor: [Steroids] explode all trees
#2 MeSH descriptor: [Hydrocortisone] explode all
trees
#3 MeSH descriptor: [Betamethasone] explode all
trees
#4 MeSH descriptor: [Prednisolone] explode all trees
#5 MeSH descriptor: [Dexamethasone] explode all
trees
#6 MeSH descriptor: [Triamcinolone] explode all trees
#7 MeSH descriptor: [Cortisone] explode all trees
#8 MeSH descriptor: [Glucocorticoids] explode all
trees
#9 MeSH descriptor: [Adrenal Cortex Hormones]
explode all trees
#10 MeSH descriptor: [Corticosterone] explode all
trees
#11 MeSH descriptor: [Hydrocortisone] explode all
trees
#12 MeSH descriptor: [18-Hydroxycorticosterone]
explode all trees
#13 MeSH descriptor: [Tetrahydrocortisol] explode all
trees
#14 MeSH descriptor: [Tetrahydrocortisone] explode
all trees
#15 MeSH descriptor: [Desoxycorticosterone] explode
all trees
#16 MeSH descriptor: [18-Hydroxydesoxycorticoster-
one] explode all trees
#17 (adrenal cortex hormon* or steroid* or cortico-
sterone or corticosteroid* or cortisol* or hydrocortisone*
or 18-hydroxycorticosterone or cortison* or tetrahydro-
cortisol or hydrocortison* or betamethason* or predniso-
lon* or methylprednisolon* or dexamethason* or
triamcinolon* or deflazacort*)
#18 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or
#9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or
#17)
#19 MeSH descriptor: [Surgical Procedures, Operative]
explode all trees
#20 MeSH descriptor: [General Surgery] explode all
trees
#21 MeSH descriptor: [Perioperative Care] explode all
trees
#22 (surg* or operat* or (perioperative near care)):ti,ab
#23 (#19 or #20 or #21 or #22)
#24 MeSH descriptor: [Pain, Postoperative] explode all
trees
#25 ((postoperative near/4 pain*) or (post-operative
near/4 pain*) or post-operative-pain* or (post* near/4
pain*) or (postoperative near/4 analgesi*) or (post-opera-
tive near/4 analgesi*) or ("post-operative analgesi*")):ti,ab,kw
#26 ((post-surgical near/4 pain*) or ("post surgical"
near/4 pain*) or (post-surgery near/4 pain*)):ti,ab,kw
#27 ("pain-relief after surg*" or "pain following surg*"
or "pain control after"):ti,ab,kw
#28 (("post surg*" or post-surg*) and (pain* or
discomfort)):ti,ab,kw
#29 ((pain* near/4 "after surg*") or (pain* near/4 "after
operat*") or (pain* near/4 "follow* operat*") or (pain*
near/4 "follow* surg*")):ti,ab,kw
#30 ((analgesi* near/4 "after surg*") or (analgesi* near/
4 "after operat*") or (analgesi* near/4 "follow* operat*")
or (analgesi* near/4 "follow* surg*")):ti,ab,kw
#31 #24 or #25 or #26 or #27 or #28 or #29 or #30
#32 #18 and #23 and #31
Additional file
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(DOCX 33 kb)
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